Eton Pharmaceuticals (ETON) Competitors $12.64 -0.10 (-0.78%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ETON vs. ARVN, DAWN, ARDX, SYRE, CALT, SNDX, SPRY, ANIP, RCKT, and BCYCShould you be buying Eton Pharmaceuticals stock or one of its competitors? The main competitors of Eton Pharmaceuticals include Arvinas (ARVN), Day One Biopharmaceuticals (DAWN), Ardelyx (ARDX), Spyre Therapeutics (SYRE), Calliditas Therapeutics AB (publ) (CALT), Syndax Pharmaceuticals (SNDX), ARS Pharmaceuticals (SPRY), ANI Pharmaceuticals (ANIP), Rocket Pharmaceuticals (RCKT), and Bicycle Therapeutics (BCYC). These companies are all part of the "pharmaceutical products" industry. Eton Pharmaceuticals vs. Arvinas Day One Biopharmaceuticals Ardelyx Spyre Therapeutics Calliditas Therapeutics AB (publ) Syndax Pharmaceuticals ARS Pharmaceuticals ANI Pharmaceuticals Rocket Pharmaceuticals Bicycle Therapeutics Eton Pharmaceuticals (NASDAQ:ETON) and Arvinas (NASDAQ:ARVN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, community ranking, valuation, media sentiment, profitability and risk. Which has stronger valuation and earnings, ETON or ARVN? Eton Pharmaceuticals has higher earnings, but lower revenue than Arvinas. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEton Pharmaceuticals$34.68M9.50-$940K-$0.22-57.45Arvinas$161.10M8.15-$367.30M-$4.67-4.09 Is ETON or ARVN more profitable? Arvinas has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -15.81%. Eton Pharmaceuticals' return on equity of -36.29% beat Arvinas' return on equity.Company Net Margins Return on Equity Return on Assets Eton Pharmaceuticals-15.81% -36.29% -16.84% Arvinas N/A -50.26%-24.87% Does the MarketBeat Community believe in ETON or ARVN? Arvinas received 95 more outperform votes than Eton Pharmaceuticals when rated by MarketBeat users. Likewise, 67.03% of users gave Arvinas an outperform vote while only 63.83% of users gave Eton Pharmaceuticals an outperform vote. CompanyUnderperformOutperformEton PharmaceuticalsOutperform Votes9063.83% Underperform Votes5136.17% ArvinasOutperform Votes18567.03% Underperform Votes9132.97% Which has more risk and volatility, ETON or ARVN? Eton Pharmaceuticals has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500. Comparatively, Arvinas has a beta of 1.82, suggesting that its stock price is 82% more volatile than the S&P 500. Does the media prefer ETON or ARVN? In the previous week, Arvinas had 6 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 13 mentions for Arvinas and 7 mentions for Eton Pharmaceuticals. Arvinas' average media sentiment score of 0.24 beat Eton Pharmaceuticals' score of 0.19 indicating that Arvinas is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eton Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arvinas 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals believe in ETON or ARVN? 27.9% of Eton Pharmaceuticals shares are held by institutional investors. Comparatively, 95.2% of Arvinas shares are held by institutional investors. 14.9% of Eton Pharmaceuticals shares are held by insiders. Comparatively, 5.2% of Arvinas shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts recommend ETON or ARVN? Eton Pharmaceuticals currently has a consensus price target of $15.00, indicating a potential upside of 18.67%. Arvinas has a consensus price target of $63.50, indicating a potential upside of 232.46%. Given Arvinas' higher probable upside, analysts plainly believe Arvinas is more favorable than Eton Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eton Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Arvinas 0 Sell rating(s) 1 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.93 SummaryArvinas beats Eton Pharmaceuticals on 11 of the 18 factors compared between the two stocks. Ad Banyan Hill PublishingTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just spent six months investigating this...and what I found is shocking.Click here and I’ll show you exactly how to position your money Get Eton Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ETON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ETON vs. The Competition Export to ExcelMetricEton PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$329.29M$6.85B$5.14B$9.31BDividend YieldN/A3.06%4.81%4.06%P/E Ratio-57.4510.75135.1917.53Price / Sales9.50287.861,232.15140.37Price / Cash3,789.3556.6540.6537.95Price / Book21.075.394.884.92Net Income-$940,000.00$152.04M$118.97M$225.78M7 Day Performance4.38%-4.32%15.41%-1.58%1 Month Performance26.02%2.80%15.47%6.67%1 Year Performance178.41%17.30%34.58%22.48% Eton Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ETONEton Pharmaceuticals2.023 of 5 stars$12.64-0.8%$15.00+18.7%+184.0%$329.29M$34.68M-57.4520ARVNArvinas2.2909 of 5 stars$19.06-2.3%$63.50+233.2%-47.9%$1.31B$78.50M-4.18445Short Interest ↑DAWNDay One Biopharmaceuticals1.9456 of 5 stars$12.78+0.2%$35.71+179.5%-11.4%$1.29B$101.95M-12.3860ARDXArdelyx3.8431 of 5 stars$5.38+3.1%$10.42+93.6%-21.2%$1.27B$251.85M-17.80267SYRESpyre Therapeutics1.9281 of 5 stars$24.75+2.6%$51.50+108.1%+63.0%$1.27B$890,000.00-3.23100CALTCalliditas Therapeutics AB (publ)N/A$40.00-0.4%$39.25-1.9%N/A$1.19B$1.60B-21.62180SNDXSyndax Pharmaceuticals3.9667 of 5 stars$13.84-0.6%$37.64+171.9%-34.4%$1.18B$16M-3.84110SPRYARS Pharmaceuticals3.0568 of 5 stars$12.13+1.9%$24.00+97.9%+125.7%$1.18B$30,000.00-23.3390ANIPANI Pharmaceuticals4.8134 of 5 stars$55.89-1.2%$77.71+39.0%+5.5%$1.18B$555.46M-102.89642Short Interest ↓RCKTRocket Pharmaceuticals4.8536 of 5 stars$11.94-0.7%$51.00+327.1%-57.9%$1.09BN/A-4.37240Analyst ForecastAnalyst RevisionBCYCBicycle Therapeutics3.5654 of 5 stars$15.39+11.4%$36.00+133.9%-13.5%$1.06B$26.98M-4.56240Analyst ForecastInsider TradeHigh Trading Volume Related Companies and Tools Related Companies ARVN Alternatives DAWN Alternatives ARDX Alternatives SYRE Alternatives CALT Alternatives SNDX Alternatives SPRY Alternatives ANIP Alternatives RCKT Alternatives BCYC Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ETON) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eton Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eton Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
